Table 2.
Effects of epigallocatechin gallate on azoxymethane-induced aberrant crypt foci in FVB mice (8th week): distribution of aberrant crypt foci along the large bowel and comparison of aberrant crypt foci in different parts
| Group | Treatment | n | Length (cm) | Rate (%) |
Number of ACF |
||
| Proximal | Distal | Entire | |||||
| 1 | Control | 5 | 9.73 ± 0.76 | / | / | / | / |
| 2 | AOM/DSS (MO) | 8 | 8.27 ± 0.37 | 100 | 1.13 ± 1.36 | 12.50 ± 3.67 | 13.13 ± 3.02 |
| 3 | AOM/DSS + 1% EGCG | 8 | 8.68 ± 0.471 | 75 | 0.63 ± 0.87 | 4.75 ± 3.702 | 5.38 ± 4.242 |
1
Different from group 2 (P < 0.05);
2
Significantly different from group 2 (P < 0.01). AOM: Azoxymethane; DSS: Dextran sodium sulfate; EGCG: Epigallocatechin gallate; ACF: Aberrant crypt foci.